Fig. 4: Immune subsets at baseline (week 0) that were associated with the best response. | British Journal of Cancer

Fig. 4: Immune subsets at baseline (week 0) that were associated with the best response.

From: A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

Fig. 4: Immune subsets at baseline (week 0) that were associated with the best response.The alternative text for this image may have been generated using AI.

a Lymphoid panel, immune cell populations identified by Boolean gating were concatenated from all live PBMC samples at week 0 and analysed by t-SNE. Gated clusters poor (teal) and good (red) responders show the overlap of major immune lineages. b CD38high B cells were associated with good (durable) responses. Analyses were done by Wilcoxon rank-sum tests with two-sided P values. c, d Kaplan–Meier curves showing better overall survival and progression-free survival of patients with PBMCs that have higher median levels of CD38high B cells. Nominal P values shown are multiple-testing corrected using the Benjamin–Hochberg method.

Back to article page